title: Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer.
abstract: We evaluated the potential of a thermoresponsive hydrogel consisting of conjugated linoleic acid-coupled Pluronic F-127 (Plu-CLA) as a controlled release, intraperitoneal delivery system for docetaxel with the aim of treating peritoneal dissemination of gastric cancer. Previously, we established a peritoneal metastasis model that involves the injection of BALB/c mice with TMK1 human gastric cancer cells. One week after the TMK1 cells were injected, the mice were injected intraperitoneally with docetaxel alone or docetaxel-loaded Plu-CLA. Tumor progression and response to therapy were monitored by micro-positron emission tomography. The total number of peritoneal tumors and the ascites volume were also measured. Compared with docetaxel alone, the combination of docetaxel and Plu-CLA (docetaxel-Plu-CLA) significantly and synergistically reduced tumor cell survival. Docetaxel-Plu-CLA showed excellent anti-tumor activity, inducing apoptosis more potently than docetaxel alone. Docetaxel-Plu-CLA also significantly reduced the number of peritoneal metastatic nodules and increased survival in the peritoneal gastric cancer xenograft model. Our results show that intraperitoneal administration of docetaxel-Plu-CLA synergistically inhibits peritoneal metastasis and prolongs survival in a peritoneal gastric cancer model. Therefore, Plu-CLA is a potential intraperitoneal-route carrier for hydrophobic docetaxel for the effective treatment of peritoneal metastatic gastric cancer.
authors.affiliation: Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanamdo, South Korea.
authors.forename: Woo Kyun
authors.initials: WK
authors.lastname: Bae
authors.forename: Myong Suk
authors.initials: MS
authors.lastname: Park
authors.forename: Ji Hee
authors.initials: JH
authors.lastname: Lee
authors.forename: Jun Eul
authors.initials: JE
authors.lastname: Hwang
authors.forename: Hyun Jeong
authors.initials: HJ
authors.lastname: Shim
authors.forename: Sang Hee
authors.initials: SH
authors.lastname: Cho
authors.forename: Dae-Eun
authors.initials: DE
authors.lastname: Kim
authors.forename: Hyang Mi
authors.initials: HM
authors.lastname: Ko
authors.forename: Chong-Su
authors.initials: CS
authors.lastname: Cho
authors.forename: In-Kyu
authors.initials: IK
authors.lastname: Park
authors.forename: Ik-Joo
authors.initials: IJ
authors.lastname: Chung
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry; D000077143:Docetaxel; D006358:Hot Temperature; D020100:Hydrogels / Q000737:chemistry; D019787:Linoleic Acid / Q000737:chemistry; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D053769:Nanocapsules / Q000008:administration & dosage* / Q000737:chemistry*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D020442:Poloxamer / Q000737:chemistry*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage* / Q000737:chemistry; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D020100:Hydrogels; D053769:Nanocapsules; D043823:Taxoids; D020442:Poloxamer; D000077143:Docetaxel; D019787:Linoleic Acid